Media stories about Innocoll Holdings (NASDAQ:INNL) have trended positive recently, according to Accern. The research firm ranks the sentiment of press coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Innocoll Holdings earned a media sentiment score of 0.31 on Accern’s scale. Accern also gave headlines about the specialty pharmaceutical company an impact score of 0 out of 100, indicating that recent press coverage is extremely unlikely to have an effect on the stock’s share price in the near term.

Several brokerages recently weighed in on INNL. FBR & Co restated a “hold” rating on shares of Innocoll Holdings in a report on Tuesday, July 4th. Zacks Investment Research lowered shares of Innocoll Holdings from a “hold” rating to a “sell” rating in a report on Tuesday, May 16th. Stifel Nicolaus lowered shares of Innocoll Holdings from a “buy” rating to a “hold” rating and cut their price objective for the company from $9.00 to $2.00 in a report on Friday, March 17th. Finally, JMP Securities upgraded shares of Innocoll Holdings to an “outperform” rating and set a $4.00 price objective on the stock in a report on Wednesday, March 29th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and one has given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus price target of $3.75.

Shares of Innocoll Holdings (NASDAQ INNL) traded down 0.44% during trading on Tuesday, reaching $2.28. 57,364 shares of the company traded hands. The company has a 50 day moving average price of $2.19 and a 200 day moving average price of $1.51. The firm’s market capitalization is $67.92 million. Innocoll Holdings has a 12-month low of $0.53 and a 12-month high of $6.51.

TRADEMARK VIOLATION WARNING: This piece of content was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece of content on another publication, it was stolen and republished in violation of U.S. and international trademark and copyright laws. The correct version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/07/11/innocoll-holdings-innl-receiving-positive-news-coverage-study-finds.html.

Innocoll Holdings Company Profile

Innocoll Holdings Public Limited Company is a commercial-stage specialty pharmaceutical and medical device company with late-stage development programs. The Company operates through the segment of manufacture and sale of collagen-based pharmaceutical products. It utilizes collagen-based technology platform to develop its biodegradable and bioresorbable products and product candidates, which can be broken down by the body without the need for surgical removal or applied topically.

Insider Buying and Selling by Quarter for Innocoll Holdings (NASDAQ:INNL)

Receive News & Stock Ratings for Innocoll Holdings Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innocoll Holdings and related stocks with our FREE daily email newsletter.